Overview

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Status:
Recruiting
Trial end date:
2022-11-02
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3041658 is effective in participants with moderate-to-severe hidradenitis suppurativa (HS).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company